Thyroid dysfunction as an unintended side effect of anticancer drugs

Thyroid

Volumn 23, Issue 11, 2013, Pages 1345-1366

  Torino, Francesco ^a   Barnabei, Agnese ^b   Paragliola, Rosamaria ^c   Baldelli, Roberto ^b   Appetecchia, Marialuisa ^b   Corsello, Salvatore Maria ^c  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; ALEMTUZUMAB; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BEXAROTENE; BLEOMYCIN; CHLORMETHINE; CISPLATIN; DACTINOMYCIN; DENILEUKIN DIFTITOX; ETOPOSIDE; IMATINIB; INTERLEUKIN 2; IPILIMUMAB; LENALIDOMIDE; NILOTINIB; PAZOPANIB; PEGINTERFERON ALPHA2B; PREDNISOLONE; PREDNISONE; PROCARBAZINE; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; THALIDOMIDE; TICILIMUMAB; TOSITUMOMAB; UNINDEXED DRUG; VINBLASTINE;

5Q- SYNDROME; ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE DISEASE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARCINOID; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COLITIS; COLORECTAL CANCER; CUTANEOUS MELANOMA; CUTANEOUS T CELL LYMPHOMA; DERMATITIS; DIARRHEA; DOSE RESPONSE; DRUG APPROVAL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOCRINE DISEASE; ENDOCRINE OPHTHALMOPATHY; GOODPASTURE SYNDROME; GRAFT VERSUS HOST REACTION; GRAVES DISEASE; HEMATOLOGIC MALIGNANCY; HEPATITIS; HEPATITIS B; HODGKIN DISEASE; HUMAN; HYPERTHYROIDISM; HYPOPHYSITIS; HYPOTHYROIDISM; INDUCTION CHEMOTHERAPY; KAPOSI SARCOMA; KIDNEY CARCINOMA; KIDNEY CLEARANCE; LOW DRUG DOSE; LUNG CANCER; MELANOMA; METASTATIC MELANOMA; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; NEUROBLASTOMA; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PANCREAS CANCER; PATHOPHYSIOLOGY; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROSTATE CANCER; RADIOIMMUNOTHERAPY; REVIEW; SIDE EFFECT; SOFT TISSUE SARCOMA; SOLID TUMOR; SUBCLINICAL HYPERTHYROIDISM; SUBCLINICAL HYPOTHYROIDISM; TESTIS CANCER; THROMBOCYTOPENIC PURPURA; THYROID CANCER; THYROID DISEASE; THYROID FUNCTION; THYROIDITIS; THYROTOXICOSIS; THYROTROPIN BLOOD LEVEL; TREATMENT DURATION; TREATMENT RESPONSE; VITILIGO;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; DIPHTHERIA TOXIN; HUMANS; HYPOTHYROIDISM; INTERFERON-ALPHA; INTERLEUKIN-2; NEOPLASMS; RECOMBINANT FUSION PROTEINS; TETRAHYDRONAPHTHALENES; THALIDOMIDE; THYROID DISEASES; THYROID GLAND; THYROID HORMONES; THYROXINE;

EID: 84887444110     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2013.0241     Document Type: Review

References (246)

1. Wartofsky L, Burman KD 1982 Alterations in thyroid function in patients with systemic illness: the "euthyroid sick syndrome." Endocr Rev 3:164-217.
2. van der Molen AJ, Thomsen HS, Morcos SK 2004 Effect of iodinated contrast media on thyroid function in adults. Eur Radiol 14:902-907. (Pubitemid 38678914)
3. Markou K, Georgopoulos N, Kyriazopoulou V, Vagenakis AG 2001 Iodine-induced hypothyroidism. Thyroid 11:501-510. (Pubitemid 32494599)
4. Schneider AB, Sarne DH 2005 Long-term risks for thyroid cancer and other neoplasms after exposure to radiation. Nat Clin Pract Endocrinol Metab 1:82-91.
5. Yeung SC, Chiu AC, Vassilopoulou-Sellin R, Gagel RF 1998 The endocrine effects of nonhormonal antineoplastic therapy. Endocr Rev 19:144-172. (Pubitemid 29114289)
6. Hamnvik OP, Larsen PR, Marqusee E 2011 Thyroid dysfunction from antineoplastic agents. J Natl Cancer Inst 103:1572-1587.
7. Bruning PF, Bonfrèr JG, Engelsman E, Hamersma-vd Linden E, de Jong-Bakker M, Nooyen W 1984 Pros and cons of aminoglutethimide for advanced postmenopausal breast cancer. Breast Cancer Res Treat 4:289-295. (Pubitemid 15189798)
8. Figg WD, Thibault A, Sartor AO, Mays D, Headlee D, Calis KA, Cooper MR 1994 Hypothyroidism associated with aminoglutethimide in patients with prostate cancer. Arch Intern Med 154:1023-1025. (Pubitemid 24144878)
9. Stava CJ, Jimenez C, Vassilopoulou-Sellin R 2007 Endocrine sequelae of cancer and cancer treatments. J Cancer Surviv 1:261-274.
10. Massart C, Le Tellier C, Lucas C, Gibassier J, Leclech G, Nicol M 1992 Effects of cisplatin on human thyrocytes in monolayer or follicle culture. J Mol Endocrinol 8:243-248.
11. Beex L, Ross A, Smals A, Kloppenborg P 1977 5-fluorouracil-induced increase of total serum thyroxine and triiodothyronine. Cancer Treat Rep 61:1291-1295. (Pubitemid 8204097)
12. Surks MI, Sievert R 1995 Drugs and thyroid function. N Engl J Med 333:1688-1694. (Pubitemid 126634606)
13. Dong BJ 2000 How medications affect thyroid function. West J Med 172:102-106.
14. Mamby CC, Love RR, Lee KE 1995 Thyroid function test changes with adjuvant tamoxifen therapy in postmenopausal women with breast cancer. J Clin Oncol 13:854-857.
15. Garnick MB, Larsen PR 1979 Acute deficiency of thyroxinebinding globulin during L-asparaginase therapy. N Engl J Med 301:252-253. (Pubitemid 9234485)
16. Ferster A, Glinoer D, Van Vliet G, Otten J 1992 Thyroid functionduringL-asparaginase therapyinchildrenwithacute lymphoblastic leukemia: difference between induction and late intensification. Am J Pediatr Hematol Oncol 14:192-196.
17. Heidemann PH, Stubbe P, Beck W 1981 Transient secondary hypothyroidism and thyroxine binding globulin deficiency in leukemic children during polychemotherapy: an effect of L-asparaginase. Eur J Pediatr 136:291-295. (Pubitemid 11093120)
18. Zatelli MC, Gentilin E, Daffara F, Tagliati F, Reimondo G, Carandina G, Ambrosio MR, Terzolo M, Degli Uberti EC 2010 Therapeutic concentrations of mitotane [o,p¢-DDD] inhibit thyrotroph cell viability and TSH expression and secretion in a mouse cell line model. Endocrinology 151: 2453-2461.
19. Daffara F, De Francia S, Reimondo G, Zaggia B, Aroasio E, Porpiglia F, Volante M, Termine A, Di Carlo F, Dogliotti L, Angeli A, Berruti A, Terzolo M 2008 Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly. Endocr Relat Cancer 15:1043-1053.
20. Stuart NS, Woodroffe CM, Grundy R, Cullen MH 1990 Long-term toxicity of chemotherapy for testicular cancer-the cost of cure. Br J Cancer 61:479-484. (Pubitemid 20106032)
21. Ssutcliffe SB, Chapman R, Wrigley PF 1981 Cyclical combination chemotherapy and thyroid function in patients with advanced Hodgkin's disease. Med Pediatr Oncol 9:439-448. (Pubitemid 12245877)
22. Hancock SL, Cox RS, McDougall IR 1991 Thyroid diseases after treatment of Hodgkin's disease. N Engl J Med 325:599-605.
23. Ogilvy-Stuart AL, Shalet SM, Gattamaneni HR 1991 Thyroid function after treatment of brain tumors in children. J Pediatr 119:733-737.
24. Paulino RC 2002 Hypothyroidism in children with medulloblastoma: a comparison of 3600 and 2340 cGy craniospinal radiotherapy. Int J Radiat Oncol Biol Phys 53:543-547.
25. Kirkwood JM 1991 Studies of interferons in the therapy of melanoma. Semin Oncol 18 (5 Suppl 7):83-90.
26. Jonasch E, Haluska FG 2001 Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 6:34-55. (Pubitemid 32155814)
27. Friedman RM 2008 Clinical uses of interferons. Br J Clin Pharmacol 65:158-162. (Pubitemid 351171276)
28. Mandac JC, Chaudhry S, Sherman KE, Tomer Y 2006 The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification. Hepatology 43:661-672.
29. Tomer Y, Blackard JT, Akeno N 2007 Interferon alpha treatment and thyroid dysfunction. Endocrinol Metab Clin North Am 36:1051-1066. (Pubitemid 350026253)
30. Merck & Co., Inc. 2012 Product information. Intron-A: interferon alfa-2b, recombinant. Available online at www .merck.com/product/usa/pi- circulars/i/intron-a/intron-a-pi.pdf (accessed April 13, 2013).
31. Koh LK, Greenspan FS, Yeo PP 1997 Interferon-alpha induced thyroid dysfunction: three clinical presentations and a review of the literature. Thyroid 7:891-896. (Pubitemid 28041664)
32. Vial T, Choquet-Kastylevsky G, Liautard C 2000 Endocrine and neurological adverse effects of the therapeutic interferons. Toxicology 142:161-172. (Pubitemid 30009867)
33. Chan WB, Chow CC, Cockram CS 2003 Interferon alpha treatment and endocrine disease. J R Soc Med 96:481-485. (Pubitemid 37289858)
34. Carella C, Mazziotti G, Amato G, Braverman LE, Roti E 2004 Interferon-a-related thyroid disease: pathophysiological, epidemiological, and clinical aspects. J Clin Endocrinol Metab 89:3656-3661. (Pubitemid 39071450)
35. Monzani F, Caraccio N, Dardano A, Ferrannini E 2004 Thyroid autoimmunity and dysfunction associated with interferon therapy. Clin Exp Med 3:199-210. (Pubitemid 38570001)
36. Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, Panagiotou P, Polyzos A, Papadopoulos O, Stratigos A, Markopoulos C, Bafaloukos D, Pectasides D, Fountzilas G, Kirkwood JM 2006 Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 354:709-718. (Pubitemid 43247141)
37. Satzger I, Meier A, Schenck F, Kapp A, Hauschild A, Gutzmer R 2007 Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low-dose interferon alpha. Int J Cancer 121:2562-2566. (Pubitemid 350022429)
38. Hauschild A, Gogas H, Tarhini A, Middleton MR, Testori A, Dréno B, Kirkwood JM 2008 Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. Cancer 112:982-994. (Pubitemid 351304581)
39. Bouwhuis MG, Ten Hagen TL, Suciu S, Eggermont AM 2011 Autoimmunity and treatment outcome in melanoma. Curr Opin Oncol 23:170-176.
40. Fentiman IS, Balkwill FR, Thomas BS, Russell MJ, Todd I, Bottazzo GF 1988 An autoimmune aetiology for hypothyroidism following interferon therapy for breast cancer. Eur J Cancer Clin Oncol 24:1299-1303.
41. Ronnblom LE, Alm GV, Oberg KE 1991 Autoimmunity after alpha interferon therapy for malignant carcinoid tumors. Ann Intern Med 115:178-183.
42. Silvestri F, Virgolini L, Mazzolini A, Bertolissi F, Russo D, Fanin R, Baccarani M 1994 Development of autoimmune thyroid diseases during long-term treatment of hematological malignancies with alpha-interferons. Haematologica 79:367-370. (Pubitemid 24301331)
43. Vallisa D, Cavanna L, Berte R, Merli F, Ghisoni F, Buscarini L 1995 Autoimmune thyroid dysfunctions in hematologic malignancies treated with alpha-interferon. Acta Haematol 93:31-35.
44. Fattovich G, Giustina G, Favarato S, Ruol A 1996 A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 24:38-47.
45. Tran HA, Jones TL, Ianna EA, Reeves GE 2011 The natural history of interferon-alpha induced thyroiditis in chronic hepatitis C patients: a long term study. Thyroid Res 4:2.
46. Marazuela M, Garcia-Buey L, Gonzalez-Fernandez B, Garća- Monzón C, Arranz A, Borque MJ, Moreno-Otero R 1996 Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-alpha therapy. Clin Endocrinol (Oxf) 44:635-642. (Pubitemid 26225178)
47. Deutsch M, Dourakis S, Manesis EK, Gioustozi A, Hess G, Horsch A, Hadziyannis S 1997 Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy. Hepatology 26:206-210. (Pubitemid 27280326)
48. Roti E, Minelli R, Giuberti T, Marchelli S, Schianchi C, Gardini E, Salvi M, Fiaccadori F, Ugolotti G, Neri TM, Braverman LE 1996 Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha. Am J Med 101: 482-487. (Pubitemid 126335968)
49. Bouwhuis MG, Suciu S, Collette S, Aamdal S, Kruit WH, Bastholt L, Stierner U, Salès F, Patel P, Punt CJ, Hernberg M, Spatz A, ten Hagen TL, Hansson J, Eggermont AM 2009 Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon. J Natl Cancer Inst 101:869-877.
50. Silvestri F, Virgolini L, Mazzolini A, Bertolissi F, Russo D, Fanin R, Baccarani M 1994 Development of autoimmune thyroid diseases during long-term treatment of hematological malignancies with alpha-interferons. Haematologica 79:367-370. (Pubitemid 24301331)
51. Pfeffer LM, Dinarello CA, Herberman RB, Williams BR, Borden EC, Bordens R, Walter MR, Nagabhushan TL, Trotta PP, Pestka S 1998 Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res 58:2489-2499. (Pubitemid 28275413)
52. Corssmit EP, de Metz J, Sauerwein HP, Romijn JA 2000 Biologic responses to IFN-alpha administration in humans. J Interferon Cytokine Res 20:1039-1047. (Pubitemid 32015242)
53. Krause I, Valesini G, Scrivo R, Shoenfeld Y 2003 Autoimmune aspects of cytokine and anticytokine therapies. Am J Med 115:390-397. (Pubitemid 37311257)
54. Lindahl P, Leary P, Gresser I 1973 Enhancement by interferon of the expression of surface antigens on murine leukemia L 1210 cells. Proc Natl Acad Sci USA 70:2785-2788.
55. Yue SJ, Enomoto T, Matsumoto Y, Kawai K, Volpe R 1998 Thyrocyte class I and class II upregulation is a secondary phenomenon and does not contribute to the pathogenesis of autoimmune thyroid disease. Thyroid 8:755-763. (Pubitemid 28535684)
56. Farrar JD, Murphy KM 2000 Type I interferons and T helper development. Immunol Today 21:484-489.
57. Tilg H 1997 New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine. Gastroenterology 112:1017-1021. (Pubitemid 27113829)
58. Caraccio N, Giannini R, Cuccato S, Faviana P, Berti P, Galleri D, Dardano A, Basolo F, Ferrannini E, Monzani F 2005 Type I interferons modulate the expression of thyroid peroxidase, sodium/iodide symporter, and thyroglobulin genes in primary human thyrocyte cultures. J Clin Endocrinol Metab 90:1156-1162. (Pubitemid 40279248)
59. Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, Jacobs S 2000 Pegylated interferonalpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther 68:556-567.
60. Eggermont AM, Bouwhuis MG, Kruit WH, Testori A, ten Hagen T, Yver A, Xu C 2010 Serum concentrations of pegylated interferon alpha-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon alpha-2b in a randomized phase III trial (EORTC 18991). Cancer Chemother Pharmacol 65:671-677.
61. Bukowski RM, Tendler C, Cutler D, Rose E, Laughlin MM, Statkevich P 2002 Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferonalpha-2b formulation. Cancer 95:389-396. (Pubitemid 34787605)
62. Eggermont AM, Suciu S, Santinami M, Testori A, Kruit WH, Marsden J, Punt CJ, Salès F, Gore M, Mackie R, Kusic Z, Dummer R, Hauschild A, Musat E, Spatz A, Keilholz U; EORTC Melanoma Group 2008 Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 372:117-126. (Pubitemid 351952257)
63. Bouwhuis MG, Suciu S, Testori A, Kruit WH, Salès F, Patel P, Punt CJ, Santinami M, Spatz A, Ten Hagen TL, Eggermont AM 2010 Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies-EORTC 18991. J Clin Oncol 28:2460-2466.
64. Weijl NI, Van der Harst D, Brand A, Kooy Y, Van Luxemburg S, Schroder J, Lentjes E, Van Rood JJ, Cleton FJ, Osanto S 1993 Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment. J Clin Oncol 11:1376-1383. (Pubitemid 23199144)
65. Atkins MB, Mier JW, Parkinson DR, Gould JA, Berkman EM, Kaplan MM 1988 Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N Engl J Med 318:1557-1563.
66. Fraenkel PG, Rutkove SB, Matheson JK, Fowkes M, Cannon ME, Patti ME, Atkins MB, Gollob JA 2002 Induction of myasthenia gravis, myositis, and insulin-dependent diabetes mellitus by high-dose interleukin-2 in a patient with renal cell cancer. J Immunother 25:373-378. (Pubitemid 34857292)
67. Krouse RS, Royal RE, Heywood G, Weintraub BD, White DE, Steinberg SM, Rosenberg SA, Schwartzentruber DJ 1995 Thyroid dysfunction in 281 patients with metastatic melanoma or renal carcinoma treated with interleukin-2 alone. J Immunother Emphasis Tumor Immunol 18:272-278. (Pubitemid 26089626)
68. Vialettes B, Guillerand MA, Viens P, Stoppa AM, Baume D, Sauvan R, Pasquier J, San Marco M, Olive D, Maraninchi D 1993 Incidence rate and risk factors for thyroid dysfunction during recombinant interleukin-2 therapy in advanced malignancies. Acta Endocrinol (Copenh) 129:31-38. (Pubitemid 23225788)
69. Schwartzentruber DJ, White DE, Zweig MH, Weintraub BD, Rosenberg SA 1991 Thyroid dysfunction associated with immunotherapy for patients with cancer. Cancer 68: 2384-2390.
70. Jacobs EL, Clare-Salzler MJ, Chopra IJ, Figlin RA 1991 Thyroid function abnormalities associated with the chronic outpatient administration of recombinant interleukin-2 and recombinant interferon-alpha. J Immunother 10:448-455.
71. Chianese-Bullock KA, Woodson EM, Tao H, Boerner SA, Smolkin M, Grosh WW, Neese PY, Merrill P, Petroni GR, Slingluff CL Jr 2005 Autoimmune toxicities associated with the administration of antitumor vaccines and low-dose interleukin-2. J Immunother 28:412-419. (Pubitemid 40962336)
72. Vassilopoulou-Sellin R, Sella A, Dexeus FH, Theriault RL, PololoffDA1992 Acute thyroid dysfunction [thyroiditis] after therapy with interleukin-2. Horm Metab Res 24:434-438.
73. Pichert G, Jost LM, Zobeli L, Odermatt B, Pedia G, Stahel RA 1990 Thyroiditis after treatment with interleukin-2 and interferon alpha-2a. Br J Cancer 62:100-104. (Pubitemid 20226454)
74. Scalzo S, Gengaro A, Boccoli G, Masciulli R, Giannella G, Salvo G, Marolla P, Carlini P, Massimini G, Holdener EE 1990 Primary hypothyroidism associated with interleukin-2 and interferon alpha-2 therapy of melanoma and renal carcinoma. Eur J Cancer 26:1152-1156.
75. Numerof RP, Aronson FR, Mier JW 1988 IL-2 stimulates the production of IL-1 alpha and IL-1 beta by human peripheral blood mononuclear cells. J Immunol 141:4250-4257. (Pubitemid 19018213)
76. Mier JW, Vachino G, van der Meer JW, Numerof RP, Adams S, Cannon JG, Bernheim HA, Atkins MB, Parkinson DR, Dinarello CA 1988 Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients. J Clin Immunol 8:426-436. (Pubitemid 19009004)
77. Lotze MT, Matory YL, Ettinghausen SE, Rayner AA, Sharrow SO, Seipp CA, Custer MC, Rosenberg SA 1985 In vivo administration of purified human interleukin 2 II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J Immunol 135:2865-2875. (Pubitemid 16217166)
78. Gemlo BT, Palladino MA Jr, Jaffe HS, Espevik TP, Rayner AA 1988 Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokineactivated killer cells. Cancer Res 48:5864-5867.
79. Pang XP, Hershman JM, Chung M, Pekary AE 1989 Characterization of tumor necrosis factor-alpha receptors in human and rat thyroid cells and regulation of the receptors by thyrotropin. Endocrinology 125:1783-1788. (Pubitemid 19258610)
80. Kragel AH, Travis WD, Feinberg L, Pittaluga S, Striker LM, Roberts WC, Lotze MT, Yang JJ, Rosenberg SA 1990 Pathologic findings associated with interleukin-2-based immunotherapy for cancer: a postmortem study of 19 patients. Hum Pathol 21:493-502. (Pubitemid 20165142)
81. Franzke A, Peest D, Probst-Kepper M, Buer J, Kirchner GI, Brabant G, Kirchner H, Ganser A, Atzpodien J 1999 Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer. J Clin Oncol 17:529-533. (Pubitemid 29075239)
82. Krouse RS, Royal RE, Heywood G, Weintraub BD, White DE, Steinberg SM, Rosenberg SA, Schwartzentruber DJ 1995 Thyroid dysfunction in 281 patients with metastatic melanoma or renal carcinoma treated with interleukin-2 alone. J Immunother Emphasis Tumor Immunol 18:272-278. (Pubitemid 26089626)
83. Phan GQ, Attia P, Steinberg SM, White DE, Rosenberg SA 2001 Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 19:3477-3482. (Pubitemid 32730084)
84. Kruit WH, Bolhuis RL, Goey SH, Jansen RL, Eggermont AM, Batchelor D, Schmitz PI, Stoter G 1993 Interleukin-2-induced thyroid dysfunction is correlated with treatment duration but not with tumor response. J Clin Oncol 11: 921-924. (Pubitemid 23146088)
85. Barbesino G 2010 Drugs affecting thyroid function. Thyroid 20:763-770.
86. Ho VT, Zahrieh D, Hochberg E, Micale E, Levin J, Reynolds C, Steckel S, Cutler C, Fisher DC, Lee SJ, Alyea EP, Ritz J, Soiffer RJ, Antin JH 2004 Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graftversus-host disease after allogeneic hematopoietic stem cell transplantation. Blood 104:1224-1226. (Pubitemid 39038048)
87. Olsen E, Duvic M, Frankel A, Kim Y, Martin A, Vonderheid E, Jegasothy B, Wood G, Gordon M, Heald P, Oseroff A, Pinter-Brown L, Bowen G, Kuzel T, Fivenson D, Foss F, Glode M, Molina A, Knobler E, Stewart S, Cooper K, Stevens S, Craig F, Reuben J, Bacha P, Nichols J 2001 Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 19:376-388. (Pubitemid 32112849)
88. Ghori F, Polder KD, Pinter-Brown LC, Hoff AO, Gagel RF, Sherman SI, Duvic M 2006 Thyrotoxicosis after denileukin diftitox therapy in patients with mycosis fungoides. J Clin Endocrinol Metab 91:2205-2208. (Pubitemid 43855006)
89. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR; Eastern Cooperative Oncology Group 2006 Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 24:431-436. (Pubitemid 46630462)
90. Shah SR, Tran TM 2007 Lenalidomide in myelodysplastic syndrome and multiple myeloma. Drugs 67:1869-1881. (Pubitemid 47347398)
91. Anderson KC 2005 Lenalidomide and thalidomide: mechanisms of action-similarities and differences. Semin Hematol 42(Suppl 4):S3-S8. (Pubitemid 41774591)
92. Badros AZ, Siegel E, Bodenner D, Zangari M, Zeldis J, Barlogie B, Tricot G 2002 Hypothyroidism in patients with multiple myeloma following treatment with thalidomide. Am J Med 112:412-413. (Pubitemid 34246272)
93. Figaro MK, Clayton W Jr, Usoh C, Brown K, Kassim A, Lakhani VT, Jagasia S 2011 Thyroid abnormalities in patients treated with lenalidomide for hematological malignancies: results of a retrospective case review. Am J Hematol 86:467-470.
94. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, Powell B, Greenberg P, Thomas D, Stone R, Reeder C, Wride K, Patin J, Schmidt M, Zeldis J, Knight R 2006 Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 355: 1456-1465. (Pubitemid 44511560)
95. Dispenzieri A, Lacy MQ, Zeldenrust SR, Hayman SR, Kumar SK, Geyer SM, Lust JA, Allred JB, Witzig TE, Rajkumar SV, Greipp PR, Russell SJ, Kabat B, Gertz MA 2007 The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood 109:465-470. (Pubitemid 46105939)
96. Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, Gisslinger H, Wiktor-Jedrzejczak W, Zodelava M, Weisel K, Cascavilla N, Iosava G, Cavo M, Kloczko J, Bladé J, Beksac M, Spicka I, Plesner T, Radke J, Langer C, Ben Yehuda D, Corso A, Herbein L, Yu Z, Mei J, Jacques C, Dimopoulos MA; MM-015 Investigators 2012 Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 366:1759-1769.
97. Somers GF 1960 Pharmacological properties of thalidomide [alpha-phthalimido glutarimide], a new sedative hypnotic drug. Br J Pharmacol Chemother 15:111-116.
98. Murdoch JM, Campbell GD 1958 Antithyroid activity of Nphthalyl glutamic acid imide [K17]. Br Med J 1:84-85.
99. Menon S, Habermann T, Witzig T 2007 Lenalidomideassociated hypothyroidism. Leuk Lymphoma 48:2465-2467.
100. Stein EM, Rivera C 2007 Transient thyroiditis after treatment with lenalidomide in a patient with metastatic renal cell carcinoma. Thyroid 17:681-683. (Pubitemid 47311559)
101. Postow M, Callahan MK, Wolchok JD 2011 Beyond cancer vaccines: a reason for future optimism with immunomodulatory therapy. Cancer J 17:372-378.
102. Leach DR, Krummel MF, Allison JP 1996 Enhancement of antitumor immunity by CTLA-4 blockade. Science 271: 1734-1736. (Pubitemid 26102823)
103. Sharma P, Wagner K, Wolchok JD, Allison JP 2011 Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer 11:805-812.
104. Tarhini A, Lo E, Minor DR 2010 Releasing the brake on the immune system: ipilimumab in melanoma and other tumors. Cancer Biother Radiopharm 25:601-613.
105. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ 2010 Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723.
106. Di Giacomo AM, Biagioli M, Maio M 2010 The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol 37:499-507.
107. Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Restifo NP, Haworth LR, Levy C, Mavroukakis SA, Nichol G, Yellin MJ, Rosenberg SA 2005 Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 23:6043-6053.
108. Yang JC, Hughes M, Kammula U, Royal R, Sherry RM, Topalian SL, Suri KB, Levy C, Allen T, Mavroukakis S, Lowy I, White DE, Rosenberg SA 2007 Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 30:825-830. (Pubitemid 350295361)
109. Kaehler KC, Piel S, Livingstone E, Schilling B, Hauschild A, Schadendorf D 2010 Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management. Semin Oncol 37: 485-498.
110. Torino F, Barnabei A, De Vecchis L, Salvatori R, Corsello SM 2012 Hypophysitis induced by monoclonal antibodies to cytotoxic T lymphocyte antigen 4: challenges from a new cause of a rare disease. Oncologist 17:525-535.
111. Juszczak A, Gupta A, Karavitaki N, Middleton MR,Grossman AB 2012 Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review. Eur J Endocrinol 167:1-5.
112. Corsello SM, Barnabei A, Marchetti P, De Vecchis L, Salvatori R, Torino F 2013 Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab 98:1361-1375.
113. Ribas A, Hauschild A, Kefford R, Punt CJ, Haanen JB, Marmol M, Garbe C, Gomez-Navarro J, Pavlov D, Marshall M 2008 Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma. J Clin Oncol 26:9011 (abstract).
114. Kirkwood JM, Lorigan P, Hersey P, Hauschild A, Robert C, McDermott D, Marshall MA, Gomez-Navarro J, Liang JQ, Bulanhagui CA 2010 Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clin Cancer Res 16:1042-1048.
115. Di Giacomo AM, Danielli R, Calabrò L, Bertocci E, Nannicini C, Giannarelli D, Balestrazzi A, Vigni F, Riversi V, Miracco C, Biagioli M, Altomonte M, Maio M 2011 Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy). Cancer Immunol Immunother 60:467-477.
116. Hodi FS, Friedlander PA, Atkins MB, McDermott DF, Lawrence DP, Ibrahim N, Wu X, Zhou J, Giobbie-Hurder A, Murphy G, Hollman T, Velazquez E, Russell S, Dipiro P, Yap JT, Van Den Abbeele AD 2011 A phase I trial of ipilimumab plus bevacizumab in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 29:8511 (abstract).
117. van den Eertwegh AJ, Versluis J, van den Berg HP 2012 Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 13:509-517.
118. Maker AV, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Hughes M, Yellin MJ, Haworth LR, Levy C, Allen T, Mavroukakis SA, Attia P, Rosenberg SA 2006 Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother 29:455-463. (Pubitemid 44288958)
119. Min L, Vaidya A, Becker C 2011 Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy. Eur J Endocrinol 164:303-307.
120. Borodic G, Hinkle DM, Cia Y 2011 Drug-induced Graves disease from ctla-4 receptor suppression. Ophthal Plast Reconstr Surg 27:e87-e88.
121. Ascierto PA, Simeone E, Sznol M, Fu YX, Melero I 2010 Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol 37:508-516.
122. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M 2012 Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443-2454.
123. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM 2012 Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455-2465.
124. Lockwood CM, Hale G, Waldman H, Jayne DR 2003 Remission induction in Behcet's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H. Rheumatology (Oxford) 42:1539-1544. (Pubitemid 37508929)
125. Bayer HealthCare Pharmaceuticals Inc. 2007 Campath product label. Available online at www.accessdata.fda .gov/drugsatfda-docs/label/2007/ 103948s5070lbl.pdf (accessed April 13, 2013).
126. Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, Margolin DH, Norris K, Tandon PK 2008 Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 359:1786-1801.
127. Shaw BE, Apperley JF, Russell NH, Craddock C, Liakopoulou E, Potter MN, Wynn R, Gibson B, Pearce RM, Kirkland K, Lee J, Madrigal JA, Cook G, Byrne JL 2011 Unrelated donor peripheral blood stem cell transplants incorporating pre-transplant in-vivo Alemtuzumab are not associated with any increased risk of significant acute or chronic graft-versus-host disease. Br J Haematol 153:244-252.
128. Kanda J, Lopez RD, Rizzieri DA 2011 Alemtuzumab for the prevention and treatment of graft-versus-host disease. Int J Hematol 93:586-593.
129. Kirk AD, Hale DA, Swanson SJ, Mannon RB 2006 Autoimmune thyroid disease after renal transplantation using depletional induction with alemtuzumab. Am J Transplant 6:1084-1085. (Pubitemid 44356662)
130. Walsh M, Chaudhry A, Jayne D 2008 Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H). Ann Rheum Dis 67:1322-1327.
131. Lorenzi AR, Clarke AM, Wooldridge T, Waldmann H, Hale G, Symmons D, Hazleman BL, Isaacs JD 2008 Morbidity and mortality in rheumatoid arthritis patients with prolonged therapy-induced lymphopenia: twelve-year outcomes. Arthritis Rheum 58:370-375. (Pubitemid 351294871)
132. Demko S, Summers J, Keegan P, Pazdur R 2008 FDA drug approval summary: alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia. Oncologist 13:167-174. (Pubitemid 351342581)
133. Coles AJ, Wing M, Smith S, Coraddu F, Greer S, Taylor C, Weetman A, Hale G, Chatterjee VK, Waldmann H, Compston A 1999 Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 354:1691-1695. (Pubitemid 29533060)
134. Coles AJ, Cox A, Le Page E, Jones J, Trip SA, Deans J, Seaman S, Miller DH, Hale G, Waldmann H, Compston DA 2006 The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 253:98-108. (Pubitemid 43157395)
135. Milenic DE, Brady ED, Brechbiel MW 2004 Antibodytargeted radiation cancer therapy. Nature Rev Drug Discovery 3:488-498.
136. Gopal AK, Rajendran JG, Gooley TA, Pagel JM, Fisher DR, Petersdorf SH, Maloney DG, Eary JF, Appelbaum FR, Press OW 2007 High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stemcell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma. J Clin Oncol 25:1396-1402. (Pubitemid 46706888)
137. Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, Leblanc M, Fisher RI 2006 Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol 24:4143-4149. (Pubitemid 46622291)
138. Kaminski MS, Tuck M, Estes J, Kolstad A, Ross CW, Zasadny K, Regan D, Kison P, Fisher S, Kroll S, Wahl RL 2005 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 352:441-449. (Pubitemid 40175970)
139. Quach A, Ji L, Mishra V, Sznewajs A, Veatch J, Huberty J, Franc B, Sposto R, Groshen S, Wei D, Fitzgerald P, Maris JM, Yanik G, Hawkins RA, Villablanca JG, Matthay KK 2011 Thyroid and hepatic function after high-dose 131 Imetaiodobenzylguanidine (131 I-MIBG) therapy for neuroblastoma. Pediatr Blood Cancer 56:191-201.
140. de Kraker J, Hoefnagel KA, Verschuur AC, van Eck B, van Santen HM, Caron HN 2008 Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age. Eur J Cancer 44:551-556.
141. van Santen HM, de Kraker J, van Eck BL, de Vijlder JJ, Vulsma T 2002 High incidence of thyroid dysfunction despite prophylaxis with potassium iodide during (131)Imeta-iodobenzylguanidine treatment in children with neuroblastoma. Cancer 94:2081-2089. (Pubitemid 34270064)
142. Fabbro D, Cowan-Jacob SW, Mö bitz H, Martiny-Baron G 2012 Targeting cancer with small-molecular-weight kinase inhibitors. Methods Mol Biol 795:1-34.
143. Lodish MB 2013 Kinase inhibitors: adverse effects related to the endocrine system. J Clin Endocrinol Metab 98:1333-1342.
144. Grossmann M, Premaratne E, Desai J, Davis ID 2008 Thyrotoxicosis during sunitinib treatment for renal cell carcinoma. Clin Endocrinol (Oxf) 69:669-672.
145. Brown RL 2011 Tyrosine kinase inhibitor-induced hypothyroidism: incidence, etiology, and management. Target Oncol 6:217-226.
146. Wolter P, Stefan C, Decallonne B, Dumez H, Bex M, Carmeliet P, Schö ffski P 2008 The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. Br J Cancer 99:448-454.
147. Desai J, Yassa L, Marqusee E, George S, Frates MC, Chen MH, Morgan JA, Dychter SS, Larsen PR, Demetri GD, Alexander EK 2006 Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 145:660-664. (Pubitemid 46768841)
148. Mannavola D, Coco P, Vannucchi G, Coco P, Vannucchi G, Bertuelli R, Carletto M, Casali PG, Beck-Peccoz P, Fugazzola L 2007 A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab 92:3531-3534. (Pubitemid 47435331)
149. Wong E, Rosen LS, Mulay M, Vanvugt A, Dinolfo M, Tomoda C, Sugawara M, Hershman JM 2007 Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid 17:351-355. (Pubitemid 46776140)
150. Shinohara N, Takahashi M, Kamishima T, Ikushima H, Otsuka N, Ishizu A, Shimizu C, Kanayama H, Nonomura K 2011 The incidence and mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma. Br J Cancer 104:241-247.
151. Baldazzi V, Tassi R, Lapini A, Santomaggio C, Carini M, Mazzanti R 2012 The impact of sunitinib-induced hypothyroidism on progression-free survival of metastatic renal cancer patients: a prospective single-center study. Urol Oncol 30:704-710.
152. Rutkowski P, Bylina E, Klimczak A, Switaj T, Falkowski S, Kroc J, Lugowska I, Brzeskwiniewicz M, Melerowicz W, Osuch C, Mierzejewska E, Wasielewski K, Woźniak A, Grzesiakowska U, Nowecki ZI, Siedlecki JA, Limon J 2012 The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure-one institution study. BMC Cancer 12:107.
153. Sabatier R, Eymard JC, Walz J, Deville JL, Narbonne H, Boher JM, Salem N, Marcy M, Brunelle S, Viens P, Bladou F, Gravis G 2012 Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma Ann Oncol 23:714-721.
154. Tamaskar I, Bukowski R, Elson P, Ioachimescu AG, Wood L, Dreicer R, Mekhail T, Garcia J, Rini BI 2008 Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Ann Oncol 19:265-268. (Pubitemid 351201706)
155. Clement P, Wolter P, Stefan C, Decallonne B, Dumez H, Wildiers H, Schö ffski P 2008 Thyroid dysfunction in patients (pts) with metastatic renal cell cancer (RCC) treated with sorafenib. J Clin Oncol 26(May 20 Suppl):16145 (abstract).
156. Miyake H, Kurahashi T, Yamanaka K, Kondo Y, Muramaki M, Takenaka A, Inoue TA, Fujisawa M 2010 Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: a prospective evaluation. Urol Oncol 28:515-519.
157. Di Lorenzo G, Carteǹ G, Autorino R, Bruni G, Tudini M, Rizzo M, Aieta M, Gonnella A, Rescigno P, Perdonà S, Giannarini G, Pignata S, Longo N, Palmieri G, Imbimbo C, De Laurentiis M, Mirone V, Ficorella C, De Placido S 2009 Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. J Clin Oncol 27:4469-4474.
158. Riesenbeck LM, Bierer S, Hoffmeister I, Köpke T, Papavassilis P, Hertle L, Thielen B, Herrmann E 2011 Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib. World J Urol 29:807-813.
159. Schmidinger M, Vogl UM, Bojic M, Lamm W, Heinzl H, Haitel A, Clodi M, Kramer G, Zielinski CC 2011 Hypothyroidism in patients with renal cell carcinoma: blessing or curse Cancer 117:534-544.
160. Kitajima K, Takahashi S, Maeda T, Yoshikawa T, Ohno Y, Fujii M, Miyake H, Fujisawa M, Sugimura K 2012 Thyroid size change by CT monitoring after sorafenib or sunitinib treatment in patients with renal cell carcinoma: comparison with thyroid function. Eur J Radiol 81:2060-2065.
161. Clemons J, Gao D, Naam M, Breaker K, Garfield D, Flaig TW 2012 Thyroid dysfunction in patients treated with sunitinib or sorafenib. Clin Genitourin Cancer 10:225-231.
162. Feldt S, Schü ssel K, Quinzler R, Franzmann A, Czeche S, Ludwig WD, Schulz M 2012 Incidence of thyroid hormone therapy in patients treated with sunitinib or sorafenib: a cohort study. Eur J Cancer 48:974-981.
163. Zhao J, Zhu Y, Zhang C, Wang X, He H, Wang H, Wu Y, ZhouW, Shen Z 2012 Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence. Urol Oncol 2012 May 30 [Epub ahead of print]; DOI: 10.1016/j.urolonc.2012.04.019.
164. Mukohara T, Nakajima H, Mukai H, Nagai S, Itoh K, Umeyama Y, Hashimoto J, Minami H 2010 Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: a phase I study in Japanese patients. Cancer Sci 101:963-968.
165. Fujiwara Y, Kiyota N, Chayahara N, Suzuki A, Umeyama Y, Mukohara T, Minami H 2012 Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients. Invest NewDrugs 30:1055-1064.
166. Tomita Y, Uemura H, Fujimoto H, Kanayama HO, Shinohara N, Nakazawa H, Imai K, Umeyama Y, Ozono S, Naito S, Akaza H; Japan Axitinib Phase II Study Group 2011 Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma. Eur J Cancer 47:2592-2602.
167. Rini BI, Wilding G, Hudes G, Stadler WM, Kim S, Tarazi J, Rosbrook B, Trask PC, Wood L, Dutcher JP 2009 Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 27:4462-4468.
168. Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, Negrier S, Ou YC, Castellano D, Lim HY, Uemura H, Tarazi J, Cella D, Chen C, Rosbrook B, Kim S, Motzer RJ 2011 Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378:1931-1939.
169. Daimon M, Kato T, Kaino W, Takase K, Karasawa S, Wada K, Kameda W, Susa S, Oizumi T, Tomita Y, Kato T 2012 Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma. Jpn J Clin Oncol 42: 742-747.
170. Joensuu H, De Braud F, Grignagni G, De Pas T, Spitalieri G, Coco P, Spreafico C, Boselli S, Toffalorio F, Bono P, Jalava T, Kappeler C, Aglietta M, Laurent D, Casali PG 2011 Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study. Br J Cancer 104:1686-1690.
171. Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Schlumberger MJ 2008 Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 359:31-42. (Pubitemid 351931094)
172. Blumenschein GR Jr., Kabbinavar F, Menon H, Mok TS, Stephenson J, Beck JT, Lakshmaiah K, Reckamp K, Hei YJ, Kracht K, Sun YN, Sikorski R, Schwartzberg L 2011 A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer. Ann Oncol 22:2057-2067.
173. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarba JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE 2010 Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28:1061-1068.
174. Matulonis UA, Berlin S, Ivy P, Tyburski K, Krasner C, Zarwan C, Berkenblit A, Campos S, Horowitz N, Cannistra SA, Lee H, Lee J, Roche M, Hill M, Whalen C, Sullivan L, Tran C, Humphreys BD, Penson RT 2009 Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol 27:5601-5606.
175. Garland LL, Chansky K, Wozniak AJ, Tsao AS, Gadgeel SM, Verschraegen CF, Dasilva MA, Redman M, Gandara DR 2011 Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509. J Thorac Oncol 6:1938-1945.
176. Asahina H, Tamura Y, Nokihara H, Yamamoto N, Seki Y, Shibata T, Goto Y, Tanioka M, Yamada Y, Coates A, Chiu YL, Li X, Pradhan R, Ansell PJ, McKeegan EM, McKee MD, Carlson DM, Tamura T 2012 An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors. Cancer Chemother Pharmacol 69:1477-1486.
177. Toh HC, Chen PJ, Carr BI, Knox JJ, Gill S, Ansell P, McKeegan EM, Dowell B, Pedersen M, Qin Q, Qian J, Scappaticci FA, Ricker JL, Carlson DM, Yong WP 2013 Phase 2 trial of Linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma. Cancer 119:380-387.
178. Tan EH, Goss GD, Salgia R, Besse B, Gandara DR, Hanna NH, Yang JC, Thertulien R, Wertheim M, Mazieres J, Hensing T, Lee C, Gupta N, Pradhan R, Qian J, Qin Q, Scappaticci FA, Ricker JL, Carlson DM, Soo RA 2011 Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer. J Thorac Oncol 6:1418-1425.
179. Weisberg E, Catley L, Wright RD, Moreno D, Banerji L, Ray A, Manley PW, Mestan J, Fabbro D, Jiang J, Hall-Meyers E, Callahan L, Della Gatta JL, Kung AL, Griffin JD 2007 Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL + leukemias. Blood 109: 2112-2120. (Pubitemid 46348213)
180. Manley PW, Drueckes P, Fendrich G, Furet P, Liebetanz J, Martiny-Baron G, Mestan J, Trappe J, Wartmann M, Fabbro D 2010 Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim Biophys Acta 1804:445-453.
181. Kim TD, Schwarz M, Nogai H, Grille P, Westermann J, Plockinger U, Braun D, Schweizer U, Arnold R, Dorken B, le Coutre P 2010 Thyroid dysfunction caused by secondgeneration tyrosine kinase inhibitors in Philadelphia chromosome positive chronic myeloid leukemia. Thyroid 20: 1209-1214.
182. Salem AK, Fenton MS, Marion KM, Hershman JM 2008 Effect of sunitinib on growth and function of FRTL-5 thyroid cells. Thyroid 18:631-635. (Pubitemid 351918450)
183. Alexandrescu DT, Popoveniuc G, Farzanmehr H, Dasanu CA, Dawson N, Wartofsky L 2008 Sunitinib-associated lymphocytic thyroiditis without circulating antithyroid antibodies. Thyroid 18:809-812. (Pubitemid 352009925)
184. Kamba T, Tam BY, Hashizume H, Haskell A, Sennino B, Mancuso MR, Norberg SM, O'Brien SM, Davis RB, Gowen LC, Anderson KD, Thurston G, Joho S, Springer ML, Kuo CJ, McDonald DM 2006 VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 290:H560-H576.
185. Rini BI, Tamaskar I, Shaheen P, Salas R, Garcia J, Wood L, Reddy S, Dreicer R, Bukowski RM 2007 Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 99:81-83.
186. Makita N, Miyakawa M, Fujita T, Iiri T 2010 Sunitinib induces hypothyroidism with a markedly reduced vascularity. Thyroid 20:323-326.
187. Rogiers A, Wolter P, Op de Beeck K, Thijs M, Decallonne B, Schö ffski P 2010 Shrinkage of thyroid volume in sunitinibtreated patients with renal-cell carcinoma: a potential marker of irreversible thyroid dysfunction Thyroid 20: 317-322.
188. Hershman JM, Liwanpo L 2010 How does sunitinib cause hypothyroidism Thyroid 20:243-244.
189. Reismuller B, Azizi AA, Peyrl A, Heinrich M, Gruber-Olipitz M, Luckner D, Rothschild KV, Slavc I 2010 Feasibility and tolerability of bevacizumab in children with primary CNS tumors. Pediatr Blood Cancer 54:681-686.
190. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK 2004 Direct evidence that the VEGF specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10:145-147. (Pubitemid 38524883)
191. Wang JF, Milosveski V, Schramek C, Fong GH, Becks GP, Hill DJ 1998 Presence and possible role of vascular endothelial growth factor in thyroid cell growth and function. J Endocrinol 157:5-12. (Pubitemid 28177487)
192. Sato K 2001 Vascular endothelial growth factors and thyroid disorders. Endocr J 48:635-646. (Pubitemid 34032333)
193. Ramsden JD 2000 Angiogenesis in the thyroid gland. J Endocrinol 166:475-480.
194. Makita N, Iiri T 2013 Tyrosine kinase inhibitor-induced thyroid disorders: a review and hypothesis. Thyroid 23:151-159.
195. de Groot JW, Zonnenberg BA, Plukker JT, van Der Graaf WT, Links TP 2005 Imatinib induces hypothyroidism in patients receiving levothyroxine. Clin Pharmacol Ther 78:433-438. (Pubitemid 41393678)
196. Dora JM, Leie MA, Netto B, Fogliatto LM, Silla L, Torres F, Maia AL 2008 Lack of imatinib-induced thyroid dysfunction in a cohort of non-thyroidectomized patients. Eur J Endocrinol 158:771-772. (Pubitemid 351639617)
197. Curran PG, DeGroot LJ 1991 The effect of hepatic enzymeinducing drugs on thyroid hormones and the thyroid gland. Endocr Rev 12:135-150.
198. Schröder-van der Elst JP, van der Heide D, DiStefano JJ 3rd, van der Bent C, Kaptein E, Visser TJ 1997 Effects of 5, 5¢-diphenylhydantoin on the metabolic pathway of thyroid hormone in rats. Eur J Endocrinol 136:324-329. (Pubitemid 27130058)
199. De Luca F, Arrigo T, Pandullo E, Siracusano MF, Benvenga S, Trimarchi F 1986 Changes in thyroid function tests induced by 2 month carbamazepine treatment in L-thyroxinesubstituted hypothyroid children. Eur J Pediatr 145: 77-79. (Pubitemid 16097674)
200. Takasu N, Takara M, Komiya I 2005 Rifampin induced hypothyroidism in patients with Hashimoto's thyroiditis. N Engl J Med 352:518-519. (Pubitemid 40175988)
201. de Groot JW, Links TP, van der Graaf WT 2006 Tyrosine kinase inhibitors causing hypothyroidism in a patient on levothyroxine. Ann Oncol 17:1719-1720. (Pubitemid 44680895)
202. Abdulrahman RM, Verloop H, Hoftijzer H, Verburg E, Hovens GC, Corssmit EP, Reiners C, Gelderblom H, Pereira AM, Kapiteijn E, Romijn JA, Visser TJ, Smit JW 2010 Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination. J Clin Endocrinol Metab 95:3758-3762.
203. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ, Brose MS 2008 Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 26:4714-4719.
204. Schlumberger MJ, Elisei R, Bastholt L, Wirth LJ, Martins RG, Locati LD, Jarzab B, Pacini F, Daumerie C, Droz JP, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Sherman SI 2009 Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 27:3794-3801.
205. Robinson BG, Paz-Ares L, Krebs A, Vasselli J, Haddad R 2010 Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab 95:2664-2671.
206. Kappers MH, van Esch JH, Smedts FM, de Krijger RR, Eechoute K, Mathijssen RH, Sleijfer S, Leijten F, Danser AH, van den Meiracker AH, Visser TJ 2011 Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression. J Clin Endocrinol Metab 96:3087-3094.
207. Ohba K, Takayama T, Matsunaga H, Matsushita A, Sasaki S, Oki Y, Ozono S, Nakamura H 2013 Inappropriate elevation of serum thyrotropin levels in patients treated with axitinib. Thyroid 24:443-448.
208. Fonseca T, Medina M, Campos M, Wittmann G, Mora-Garzon M, Ueta C, Arrojo e Drigo R, Werneck-de-Castro J, Caicedo D, Gereben B, Fekete C, Lechan R, Bianco AC 2012 Pituitary-specific inactivation of type II deiodinase (D2) reveals coordination between the conversion of T4 to T3 in thyrothrophs and in tanycytes in the T4-mediated TSH feedback mechanism. Thyroid 22:A10 (abstract).
209. Braun D, Kim TD, le Coutre P, Kohrle J, Hershman JM, Schweizer U 2012 Tyrosine kinase inhibitors noncompetitively inhibit MCT8-mediated iodothyronine transport. J Clin Endocrinol Metab 97:E100-E105.
210. Kliewer SA, Umesono K, Mangelsdorf DJ, Evans RM 1992 Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling. Nature 355:446-449.
211. Keller H, Dreyer C, Medin J, Mahfoudi A, Ozato K, Wahli W 1993 Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc Natl Acad Sci USA 90:2160-2164. (Pubitemid 23078585)
212. Duvic M, Hymes K, Heald P, Breneman D, Martin AG, Myskowski P, Crowley C, Yocum RC; Bexarotene Worldwide Study Group 2001 Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 19:2456-2471. (Pubitemid 32391217)
213. Haugen BR 2009 Drugs that suppress TSH or cause central hypothyroidism. Best Pract Res Clin Endocrinol Metab 23:793-800.
214. Golden WM, Weber KB, Hernandez TL, Sherman SI, Woodmansee WW, Haugen BR 2007 Single-dose rexinoid rapidly and specifically suppresses serum thyrotropin in normal subjects. J Clin Endocrinol Metab 92:124-130. (Pubitemid 46067519)
215. Sherman SI, Gopal J, Haugen BR, Chiu AC, Whaley K, Nowlakha P, Duvic M 1999 Central hypothyroidism associated with retinoid X receptor-selective ligands. N Engl J Med 340:1075-1079. (Pubitemid 29162512)
216. Duvic M, Martin AG, Kim Y, Olsen E, Wood GS, Crowley CA, Yocum RC; Worldwide Bexarotene Study Group 2001 Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent earlystage cutaneous T-cell lymphoma. Arch Dermatol 137:581-593. (Pubitemid 32458440)
217. Sharma V, Hays WR, Wood WM, Pugazhenthi U, St. Germain DL, Bianco AC, Krezel W, Chambon P, Haugen BR 2006 Effects of rexinoids on thyrotrope function and the hypothalamic-pituitary-thyroid axis. Endocrinology 147: 1438-1451. (Pubitemid 43244378)
218. Liu S, Ogilvie KM, Klausing K, Lawson MA, Jolley D, Li D, Bilakovics J, Pascual B, Hein N, Urcan M, Leibowitz MD 2002 Mechanism of selective retinoid X receptor agonistinduced hypothyroidism in the rat. Endocrinology 143: 2880-2885. (Pubitemid 34809858)
219. Smit JW, Stokkel MP, Pereira AM, Romijn JA, Visser TJ 2007 Bexarotene-induced hypothyroidism: bexarotene stimulates the peripheral metabolism of thyroid hormones. J Clin Endocrinol Metab 92:2496-2499. (Pubitemid 47037348)
220. Howell SR, Shirley MA, Ulm EH 1998 Effects of retinoid treatment of rats on hepatic microsomal metabolism and cytochromes P450. Correlation between retinoic acid receptor/retinoid x receptor selectivity and effects on metabolic enzymes. Drug Metab Dispos 26:234-239. (Pubitemid 28182399)
221. O'Connor P, Feely J 1987 Clinical pharmacokinetics and endocrine disorders. Therapeutic implications. Clin Pharmacokinet 13:345-364. (Pubitemid 18024722)
222. Chen SY, Kao PC, Lin ZZ, Chiang WC, Fang CC 2009 Sunitinib-induced myxedema coma. Am J Emerg Med 27:370.e1-370.e3.
223. Collinson F, Vasudev N, Berkin L, Khan MM, Selby PJ, Brown JE 2011 Sunitinib-induced severe hypothyroidism with cardiac compromise. Med Oncol 28(Suppl 1):S699-S701.
224. Di Lorenzo G, Autorino R, Bruni G, Carteǹ G, Ricevuto E, Tudini M, Ficorella C, Romano C, Aieta M, Giordano A, Giuliano M, Gonnella A, De Nunzio C, Rizzo M, Montesarchio V, Ewer M, De Placido S 2009 Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann Oncol 20:1535-1542.
225. Cristofanilli M, Yamamura Y, Kau SW, Bevers T, Strom S, Patangan M, Hsu L, Krishnamurthy S, Theriault RL, Hortobagyi GN 2005 Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma. Cancer 103:1122-1128. (Pubitemid 40328081)
226. Angelousi AG, Anagnostou VK, Stamatakos MK, Georgiopoulos GA, Kontzoglou KC 2012 Mechanisms in endocrinology: primary HT and risk for breast cancer: a systematic review and meta-analysis. Eur J Endocrinol 166:373-381.
227. Nelson M, Hercbergs A, Rybicki L, Strome M 2006 Association between development of hypothyroidism and improved survival in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 132:1041-1046. (Pubitemid 44600780)
228. Hercbergs AA, Goyal LK, Suh JH, Lee S, Reddy CA, Cohen BH, Stevens GH, Reddy SK, Peereboom DM, Elson PJ, Gupta MK, Barnett GH 2003 Propylthiouracil- induced chemical hypothyroidism with high-dose tamoxifen prolongs survival in recurrent high grade glioma: a phase I/II study. Anticancer Res 23:617-626. (Pubitemid 36358462)
229. Wolter P, Stefan C, Decallonne B, Dumez H, Bex M, Carmeliet P, Schö ffski P 2008 Evaluation of thyroid dysfunction as a candidate surrogate marker for efficacy of sunitinib in patients [pts] with advanced renal cell carcinoma [RCC]. J Clin Oncol 26(Suppl 15):5126 (abstract).
230. Yang JC, Hughes M, Kammula U, Royal R, Sherry RM, Topalian SL, Suri KB, Levy C, Allen T, Mavroukakis S, Lowy I, White DE, Rosenberg SA 2007 Ipilimumab [anti-CTLA4 antibody] causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 30:825-830. (Pubitemid 350295361)
231. Agarwala SS, Ribas A 2010 Current experience with CTLA4-blocking monoclonal antibodies for the treatment of solid tumors. J Immunother 33:557-569.
232. Torino F, Corsello SM, Longo R, Barnabei A, Gasparini G 2009 Is hypothyroidism a clinically relevant toxicity of tyrosine kinase inhibitors Thyroid 19:539-540.
233. Eisen T, Sternberg CN, Robert C, Mulders P, Pyle L, Zbinden S, Izzedine H, Escudier B 2012 Targeted therapies for renal cell carcinoma: review of adverse event management strategies. J Natl Cancer Inst 104:93-113.
234. Torino F, Corsello SM, Longo R, Barnabei A, Gasparini G 2009 Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat Rev Clin Oncol 6:219-228.
235. Assaf C, Bagot M, Dummer R, Duvic M, Gniadecki R, Knobler R, Ranki A, Schwandt P, Whittaker S 2006 Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion. Br J Dermatol 155:261-266. (Pubitemid 44050557)
236. Sherman SI 2003 Etiology, diagnosis, and treatment recommendations for central hypothyroidism associated with bexarotene therapy for cutaneous T-cell lymphoma. Clin Lymphoma 3:249-252. (Pubitemid 36416851)
237. Bristol-Myers Squibb. Yervoy (ipilimumab): serious and fatal immune-mediated adverse reactions. www.yervoy .com/hcp/rems.aspx (accessed April 13, 2013).
238. Illouz F, Laboureau-Soares S, Dubois S, Rohmer V, Rodien P 2009 Tyrosine kinase inhibitors and modifications of thyroid function tests: a review. Eur J Endocrinol 160:331-336.
239. Baskin HJ, Cobin RH, Duick DS, Gharib H, Guttler RB, Kaplan MM, Segal RL 2002 American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract 8:457-469.
240. Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, Franklyn JA, Hershman JM, Burman KD, Denke MA, Gorman C, Cooper RS, Weissman NJ 2004 Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 291:228-238. (Pubitemid 38082818)
241. Cooper DS, Biondi B 2012 Subclinical thyroid disease. Lancet 379:1142-1154.
242. Garfield DH, Hercbergs A, Davis PJ 2007 Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 99:975-976. (Pubitemid 47073506)
243. Lin HY, Sun M, Tang HY, Lin C, Luidens MK, Mousa SA, Incerpi S, Drusano GL, Davis FB, Davis PJ 2009 L-thyroxine vs. 3, 5, 3¢-triiodo-L-thyronine and cell proliferation: activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Am J Physiol Cell Physiol 296:C980-C991.
244. Davis PJ, Davis FB, Lin HY, Bergh JJ, Mousa S, Hercbergs A, Fenstermaker RA, Ciesielski MJ 2007 Cell surface receptor for thyroid hormone and tumor cell proliferation. Exp Rev Endocrinol Metabol 1:753-761.
245. Hamnvik OP, Larsen PR, Marqusee E 2012 Response: Re: Thyroid dysfunction from antineoplastic agents. J Natl Cancer Inst 104:423.
246. Hercbergs AA, Garfield D, Ashur-Fabian O, Davis PJ 2012 Re: Thyroid dysfunction from antineoplastic agents. J Natl Cancer Inst 104:422-423.